Lantheus Appoints Jamie Spaeth as Chief People Officer

By: Lantheus Holdings, Inc. via GlobeNewswire

July 08, 2024 at 08:30 AM EDT

BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Jamie Spaeth to its Executive Team as Chief People Officer.

“We’re excited to have Jamie join Lantheus as we continue to harness our team’s potential to deliver innovative solutions to serve patients and healthcare professionals,” said Dan Niedzwiecki, Chief Administrative Officer of Lantheus. “At Lantheus, our people drive our success, and Jamie’s proven leadership and expertise will foster a collaborative, high-performing culture where employees feel included and connected to our purpose and values.”

“I’m thrilled to join this purpose-driven organization and to elevate its already-strong culture focused on delivering better patient outcomes,” said Ms. Spaeth. “I look forward to working closely with the Executive Team and everyone at Lantheus to engage, attract and develop the talent we need to advance the Company’s strategy as the leading radiopharmaceutical-focused company.”

Ms. Spaeth has nearly 20 years of broad Human Resources experience in the biotechnology and pharmaceutical industries. Most recently, Ms. Spaeth was the Chief People Officer at Corium, a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies. Prior to Corium, she served as Head of HR, R&D, Technical Operations and G&A, at Sage Therapeutics. In addition, Ms. Spaeth spent 12 years at Shire in various HR roles of increasing responsibilities. Ms. Spaeth currently serves as an advisor to the Kristine Pettoni Foundation, a non-profit organization dedicated to supporting women in their efforts to rejoin the workforce, progress in their careers and attain financial stability. She has a Bachelor of Science in Hospitality and Tourism Management from The University of Massachusetts and a Master of Science in Human Resources from Suffolk University.

About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.

Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “continue,” “look forward,” “will” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements are discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).

Contacts:

Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com

About Us

Additional Information

Website & Technical Help

Lantheus Appoints Jamie Spaeth as Chief People Officer

More News